Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development

Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 200 disease targets.